# COU-AA-302 (abiraterone acetate): what clinicians are saying

> 266 statements from 37 sources (2 podcasts, 5 videos, 15 posts, 15 papers), 19 of them from 7 confirmed clinicians, each linked to its source. Commentary checked Nov 14, 2026.

## Report

- Trial: A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
- NCT ID: NCT00887198
- Registry: https://clinicaltrials.gov/study/NCT00887198
- Sponsor: Janssen Research & Development, LLC
- Phase: Phase 3
- Status: Completed
- Drugs tested: abiraterone acetate
- Indication: chemotherapy-naive metastatic castration-resistant prostate cancer
- Version: v1.0.0, edition 1
- Accepted: 2026-11-14 UTC
- Last checked: 2026-11-14 UTC
- Release hash: b55fc20f9baf6d7817a6572753ca86076512ff46e10bd28b5a33895f4833d2cb

## Counts

- Commentary sources screened: 120
- Sources cited by verified statements: 37
- Verified statements: 266
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 19
- Findings: 11
- Named people in screened sources (unnamed speakers and accounts not counted): 18
- Speakers cited: 17
- Cited speakers with a verified identity: 12
- Cited clinicians, speakers with a confirmed clinical role (the abstract's clinicians): 7
- Of them physicians, whose confirmed role is a physician's, not a physician assistant's, nurse's or pharmacist's (the abstract's physicians): 7
- By role and specialty (the abstract's specialty counts):
  - 5 physician, Medical oncology
  - 2 physician, Radiation oncology
- Organisational or shared accounts (not counted as people): 2

A verified identity says who a speaker is. A cited clinician also has a clinical role confirmed by the NPI registry or their own institution's staff page. Verified speakers without such a role, such as researchers, advocates, company staff, or clinicians whose role only a source or their own profile states, are not counted as clinicians.

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

One speaker reads COU-AA-302 as supporting abiraterone through chemotherapy deferral but would probably choose enzalutamide for simpler treatment, while considering abiraterone for high falls risk. A medical oncologist sees a clear survival advantage as reshaping care previously centered on docetaxel; the first speaker finds the final survival gain smaller than expected. That treatment preference is not demonstrated superiority: the cross-trial discussion cannot establish relative benefit, and prednisone's anticancer dose effect remains unresolved.

## Question clinicians left open

What clinical or biological features do clinicians say could guide choosing abiraterone acetate plus prednisone rather than enzalutamide in COU-AA-302’s asymptomatic or mildly symptomatic, chemotherapy-naive metastatic castration-resistant prostate cancer setting without prior ARPI exposure, beyond comorbidities and tolerability?

From finding F1 (23 statements from 2 speakers in 5 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. One speaker would probably favor enzalutamide for uncomplicated mCRPC, while preserving reasons to consider abiraterone
  - 23 statements from 2 speakers in 5 sources, 4 of them podcasts or videos.
- F2. One speaker reads cross-trial results as numerically favoring enzalutamide over abiraterone; commentary weighs population, endpoint, steroid-control and crossover caveats.
  - 13 statements from 1 speaker in 2 sources, all podcasts or videos.
- F3. Speakers regard pre-chemotherapy abiraterone as a major advance, but differ in how strongly they describe its survival value
  - 20 statements from 4 speakers in 7 sources, 3 of them podcasts or videos.
- F4. Speakers give symptom control and chemotherapy deferral substantial clinical weight
  - 10 statements from 4 speakers in 8 sources, 2 of them podcasts or videos.
- F5. Whether reducing prednisone improves the abiraterone trade-off remains an open question in one podcast exchange
  - 18 statements in 3 sources, 2 of them podcasts or videos.
- F6. One safety interview offers strong long-term reassurance, while other discussions emphasize patient-specific risks
  - 17 statements from 1 speaker in 6 sources, 3 of them podcasts or videos.
- F7. Speakers see oral abiraterone as widening treatment opportunity; one X account questions the cost of earlier use
  - 12 statements from 3 speakers in 6 sources, 4 of them podcasts or videos.
- F8. One X account finds prior-local-therapy analyses reassuring, but not evidence of a causal survival gain
  - 6 statements from 1 speaker in 3 sources.
- F9. A podcast speaker and an X account discourage serial ARPI use; the episode separates intolerance from progression
  - 22 statements from 2 speakers in 4 sources, 1 of them a podcast or video.
- F11. One speaker favors enzalutamide–radium-223, while one X account relays no OS benefit for a different intensification approach
  - 5 statements from 2 speakers in 3 sources, 1 of them a podcast or video.
- F14. A discussion weighs androgen biology, one prolonged abiraterone response and unvalidated selection hypotheses; a publication reports benefit across ERG groups without statistically significant differential benefit.
  - 20 statements in 2 sources, 1 of them a podcast or video.

The full report also has 4 findings about other patients, lines of treatment or settings, after these trial findings under “Beyond the trial population”. They are not counted or listed on this page.

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding. Speakers are the named people a finding's statements cite, of any role, counted as the report counts its cited speakers; unnamed speakers and accounts are not counted.

| Finding | Statements | Passages | Sources | Speakers | Limitations |
| --- | ---: | ---: | ---: | ---: | ---: |
| F1 | 23 | 16 | 5 | 2 | 3 |
| F2 | 13 | 10 | 2 | 1 | 2 |
| F3 | 20 | 19 | 7 | 4 | 2 |
| F4 | 10 | 12 | 8 | 4 | 3 |
| F5 | 18 | 8 | 3 | 0 | 2 |
| F6 | 17 | 13 | 6 | 1 | 2 |
| F7 | 12 | 10 | 6 | 3 | 2 |
| F8 | 6 | 6 | 3 | 1 | 2 |
| F9 | 22 | 16 | 4 | 2 | 2 |
| F11 | 5 | 3 | 3 | 2 | 2 |
| F14 | 20 | 15 | 2 | 0 | 2 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Statement links to supporting passages | Statement links to context passages | Sources by kind |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- |
| F1 | 17 | 3 | 1 | 2 | 0 | 25 | 6 | 1 post or article, 4 podcasts and video |
| F2 | 7 | 1 | 0 | 4 | 1 | 17 | 2 | 2 podcasts and video |
| F3 | 9 | 0 | 1 | 2 | 8 | 24 | 2 | 2 posts and articles, 3 podcasts and video, 2 publications |
| F4 | 4 | 0 | 0 | 0 | 6 | 12 | 0 | 3 posts and articles, 2 podcasts and video, 3 publications |
| F5 | 4 | 6 | 1 | 3 | 4 | 22 | 0 | 2 podcasts and video, 1 publication |
| F6 | 7 | 2 | 1 | 1 | 6 | 20 | 1 | 3 podcasts and video, 3 publications |
| F7 | 3 | 0 | 2 | 3 | 4 | 13 | 0 | 2 posts and articles, 4 podcasts and video |
| F8 | 4 | 0 | 0 | 0 | 2 | 6 | 0 | 3 posts and articles |
| F9 | 13 | 5 | 0 | 2 | 2 | 23 | 3 | 2 posts and articles, 1 podcast or video, 1 publication |
| F11 | 3 | 0 | 0 | 1 | 1 | 5 | 0 | 2 posts and articles, 1 podcast or video |
| F14 | 7 | 0 | 5 | 2 | 6 | 27 | 1 | 1 podcast or video, 1 publication |

### Trial dimensions

- Primary endpoint: Overall Survival: F2 (2 shared claims), F3 (7 shared claims), F4 (3 shared claims), F7 (1 shared claims)
- Primary endpoint: Radiographic Progression-free Survival (rPFS): F3 (4 shared claims), F4 (2 shared claims), F7 (1 shared claims)
- Secondary endpoints: F3 (1 shared claims), F4 (7 shared claims), F7 (1 shared claims)
- Population and setting: F1 (1 shared claims), F2 (2 shared claims), F3 (5 shared claims), F4 (1 shared claims), F7 (3 shared claims), F11 (1 shared claims)
- The comparison: F2 (7 shared claims), F3 (1 shared claims), F5 (4 shared claims)
- Safety and tolerability: F1 (4 shared claims), F5 (5 shared claims), F6 (13 shared claims)
- Design and conduct: F2 (3 shared claims), F3 (4 shared claims), F4 (2 shared claims), F7 (1 shared claims)

## Abbreviations

- ARPI: androgen receptor pathway inhibitor
- HCP: healthcare professional
- MCP: Model Context Protocol, how AI agents read the report
- NPI: National Provider Identifier, the US registry number for clinicians
- OS: overall survival

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 11 | Titles free |
| Detailed analysis | 17 sections | Paid |
| Verified statements with short source quotes and links | 266 | Paid |
| Who said each statement: the cited speakers | 17 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 7 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 12 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 14 | Free |
| Sources with links | 37 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |

Every edition, the free report included, names who said each statement, as the source shows them. Each named speaker's card gives a clinical role only when the NPI registry or the person's own institution's staff page confirms it, and says which; a role only a source states is labelled as the source's. Here 7 of the 17 cited speakers have a role confirmed that way. Every edition also comes with MCP access, so your AI agent reads the same evidence with your license key, and with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself. Social accounts are not included. The IDs are for checking attribution inside your organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.

## Trial aspects

14 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Overall Survival | discussed | 9 | 6 |
| Primary endpoint: Radiographic Progression-free Survival (rPFS) | discussed | 5 | 3 |
| Secondary endpoints | discussed | 7 | 5 |
| Population and setting | discussed | 13 | 4 |
| The comparison (The registered arms and what clinicians said about how they compare.) | discussed | 10 | 3 |
| Safety and tolerability | discussed | 17 | 3 |
| Design and conduct | discussed | 9 | 3 |
| First-line choice, comorbidity and patient burden | discussed | 25 | 5 |
| Prednisone's physiological and anticancer roles | discussed | 17 | 2 |
| Chemotherapy alternatives, treatment opportunity and cost | discussed | 13 | 6 |
| Prior local therapy and interpretation of subgroup associations | discussed | 4 | 2 |
| Exposure-defined pathways, progression and intolerance exceptions | discussed | 8 | 3 |
| Alternative combinations and regimen-specific bone protection | discussed | 5 | 3 |
| Development experience, exceptional response and predictive biology | discussed | 15 | 1 |

Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.

## Sources

| Channel | Statements | Cited | Screened |
| --- | ---: | ---: | ---: |
| **Video & audio · 108 statements · 41%** (from 7 videos and episodes · about 15 per source) | | | |
| YouTube | 17 | 3 | 3 |
| X videos | 4 | 2 | 2 |
| Podcasts | 87 | 2 | 2 |
| **Posts · 20 statements · 7%** (from 15 posts · about 1 per source) | | | |
| X threads | 20 | 15 | 113 |
| **Primary sources · 138 statements · 52%** (cited for context, not screened · from 15 sources · about 9 per source) | | | |
| Publications (primary source, cited for context) | 138 | 15 | not screened |

- Screened window: 2012-06-11 to 2026-09-14
- Cited window: 2012-08-09 to 2026-09-14
- Retrieved: 2026-11-14

Statements count each verified statement once, split evenly over the sources it cites. Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
- Registry: NCT00887198 (https://clinicaltrials.gov/study/NCT00887198)
- Study IDs: CR016927 · COU-AA-302 (Janssen Research & Development, LLC) · 2008-008004-41
- Sponsor: Janssen Research & Development, LLC
- Design: Phase 3 · interventional, randomized, parallel, phase3
- Status: Completed
- Enrollment: 1,088 (actual)
- Start: 2009-04-28 (actual)
- Primary completion: 2014-03-31 (actual)
- Primary endpoint: Overall Survival (From randomization (Day 1) up to end of study (Month 60))
- Primary endpoint: Radiographic Progression-free Survival (rPFS) (From randomization (Day 1) up to first radiographic progression or cutoff date (Month 18))
- Intervention: Abiraterone acetate (drug)
- Intervention: Placebo (drug)
- Intervention: Prednisone (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- For 1 recording, a transcript separated by speaker was not available, so quotes come from the original automatic transcript and may lack speaker labels.
- Not yet captured in this edition: a view on distinguishing newer androgen receptor inhibitors from first-generation agents when considering abiraterone alternatives in castration-resistant prostate cancer; a view on androgen receptor pathway inhibition versus chemotherapy in metastatic castration-resistant prostate cancer after androgen deprivation alone; a view on prednisone’s potential benefits and harms in interpreting abiraterone trial controls and cross-trial comparisons; a view on antiandrogen therapy’s place among systemic treatment options for metastatic castration-resistant prostate cancer; a view on crossover and secondary outcomes when weighing alternative therapy in chemotherapy-naive metastatic castration-resistant prostate cancer.
- 149 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 45 sources about other trials or topics are not included.
- These sources are not a representative sample of HCP opinion. Source totals, reposts and nested relays cannot be interpreted as independent-clinician counts or consensus.
- Several spoken passages cannot be assigned to a named participant. They are attributed to their episode or discussion and are not counted as separate people.
- The PREVAIL comparison is incompletely represented, including crossover, subsequent-treatment, chemotherapy-delay, quality-of-life and skeletal-event context.
- The available account of an ongoing prednisone analysis and suggested negative aspect does not fully support characterization of its evidence or ownership.
- Coverage of comments about alternatives to ARPI monotherapy, later-line treatment options and earlier antiandrogen evidence is incomplete. The options described here should not be read as everything discussed in those exchanges.
- No separate protocol was available. Full text was unavailable for the rPFS-biomarker and initial-Gleason-score papers, limiting assessment of their detailed methods and qualifications.
- Discussion that does not name COU-AA-302 or uses different terminology may be missing. Absence from this edition does not establish absence from public discussion.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- Cross-trial comparisons, historical controls, retrospective subgroups, early-phase research and individual patient experiences are preserved as such; none establishes head-to-head superiority or a validated new treatment-selection rule.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, edition 1, accepted 2026-11-14 UTC: current edition

Each new edition gets a new version: a new or changed finding raises the middle number (1.0.0 to 1.1.0), added evidence or newly verified speakers alone the last number (1.0.0 to 1.0.1), and a change of report format the first number. A correction fixes the published edition in place without making a new edition, so the version stays the same. Changes are corrections that add, remove or change a statement or finding, or withdraw a source; routine maintenance (people cards, names and spellings, recounts, tags and page wording) changes none. Every correction is listed here with its date. Last checked for new commentary 2026-11-14 UTC. No changes.

## Offer

- Size: Standard · 266 verified statements · 19 from 7 confirmed clinicians
- Current edition: $1,250. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of updates: $2,200
- 6 months of updates: $3,100
- 12 months of updates: $4,400
- Every product includes verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself (12 identity-verified speakers now); social accounts are not included. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/cou-aa-302-nct00887198
- Agents: POST https://www.erudio.com/api/orders with {"report": "cou-aa-302-nct00887198", "product": "edition" | "updates-3" | "updates-6" | "updates-12", "buyer_email": "...", "organization": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user and a pay_url your own payment client can pay over HTTP 402 in USDC, with MPP (on Tempo) or x402 (on Base), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=cou-aa-302-nct00887198

## Cite

Erudio Health. COU-AA-302 (NCT00887198): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 14, 2026. https://www.erudio.com/reports/cou-aa-302-nct00887198

## Questions

### How much does the COU-AA-302 report cost?

One edition costs $1,250 (Standard · 266 verified statements · 19 from 7 confirmed clinicians). With updates: 3 months $2,200, 6 months $3,100, 12 months $4,400. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.

### What does the COU-AA-302 report cover?

266 statements from 37 sources (2 podcasts, 5 videos, 15 posts, 15 papers), 19 of them from 7 confirmed clinicians, each linked to its source. Commentary checked Nov 14, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.

### Can my AI agent read or buy the COU-AA-302 report?

Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "cou-aa-302-nct00887198" }) previews it and create_order({ "report": "cou-aa-302-nct00887198", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. [Connect your AI client](https://www.erudio.com/developers/connect)

### How current is the COU-AA-302 report?

Edition 1 (version 1.0.0), accepted Nov 14, 2026 UTC; last checked for new commentary Nov 14, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.

## Machine access

- JSON: https://www.erudio.com/reports/cou-aa-302-nct00887198.json
- Markdown: https://www.erudio.com/reports/cou-aa-302-nct00887198.md
- Change feed (JSON Feed: new editions and changes): https://www.erudio.com/reports/cou-aa-302-nct00887198/feed.json
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "cou-aa-302-nct00887198"}`